Kontra's weekly script check shows total GLP-1 prescriptions up 0.4%, with Novo under pressure in obesity but making gains in oral diabetes.
Recap by typeshit. Post by Kontra on X.
The MFDS approval rests on SURPASS-CVOT, where Mounjaro matched Trulicity on heart events in 13,000+ patients but did not prove superior.
Inside Retail Asia looks at skincare and aesthetic treatments brands are building for facial volume loss after rapid weight loss.
The actor told an interviewer people can take Ozempic carefree, while stressing that nothing replaces actually working out.
CFO MV Narasimham says the company still expects to ship 6 to 7 million pens across 10 approved markets between November and March, with Canada taking most of them.
The Motley Fool points to a biosimilar approval target and supply fixes as the setup for wider margins while legacy drugs drag on growth.
Aimed at Marathi speakers, the post says social media spreads more rumors than facts about semaglutide and GLP-1 agonists used for obesity management.
Loading…